RxDoctor Payments Data

Jon Thomas, MD

Family Medicine · Council Bluffs, IANPI 1437209434

Payments from drug & device makers

$1,713in general payments, 2019–2025

Across 104 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$290
  • Amgen$195
  • Boston Scientific$136
  • Novo Nordisk$135
  • Boehringer Ingelheim$105
  • Insulet Corporation$92
  • plus $759 from 24 others

What the payments were for

  • Food & beverage$1,713100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,713 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$196,346
Medicare patients
409
Services billed
4,882

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$240,061
MounjaroTirzepatide111$135,495
TrulicityDulaglutide97$98,058
XareltoRivaroxaban98$94,491
OzempicSemaglutide59$85,167
BiktarvyBictegrav/Emtricit/Tenofov Ala11$42,915
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$39,174
LinzessLinaclotide51$38,114
JanuviaSitagliptin Phosphate33$27,158
JardianceEmpagliflozin31$26,939
FarxigaDapagliflozin Propanediol24$25,577
MyrbetriqMirabegron35$18,912
SymbicortBudesonide/Formoterol Fumarate57$16,778
Incruse ElliptaUmeclidinium Bromide42$15,448
QuliptaAtogepant12$13,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$29$233,553208 claims
Johnson & JohnsonXarelto$12$94,49198 claims
Novo NordiskOzempic$135$85,16759 claims
AbbVieLinzess, Qulipta$290$51,30063 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$36$50,10293 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$105$46,37657 claims
MerckJanuvia$37$27,15833 claims
Astellas Pharma US IncMyrbetriq$85$18,91235 claims
Sanofi-aventis U.S. LLCLantus$11$4,09522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →